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Protein kinase C (PKC) is normally activated by diacylglycerol in the presence of Ca* + and phosphatidylserine. At phy- 
siological concentrations of Ca *+ , however, phosphatidylethanol, a product of the phospholipase D-catalyzed transphos- 
phatidylation reaction between membrane phospholipids and ethanol, can replace phosphatidylserine, and activate PKC. 
This mode of activation is most effective for the y-subspecies, which is expressed only in central nervous tissue. Phospha- 
tidylmethanol is also effective to some extent. Consideration of these results suggests the possibility that ethanol may 
exert some effect on signal transduction in this tissue via changes in protein phosphorylation. 
Protein kinase C; Phosphatidylethanol; Ethanol; Phospholipase D 
1. INTRODUCTION 
Protein kinase C (PKC) is normally activated by 
diacylglycerol in the presence of Ca2+ and acidic 
phospholipids (review [ 11). At physiologically low 
concentrations of Ca’+, phosphatidylserine is in- 
dispensable for the enzyme activation [2]. Phos- 
pholipase D has been known for some time to 
catalyze the transphosphatidylation reaction be- 
tween various membrane phospholipids and 
alcohols such as ethanol [3,4]. In this reaction 
phosphatidylcholine is the most effective phos- 
phatidyl donor [3]. In fact, phosphatidylethanol 
has been found in the brain, heart, kidney, liver 
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and skeletal muscle tissue of ethanol-treated rats 
[5-71. 
Recent analysis of cDNA clones indicates the 
presence of several subspecies of PKC in brain 
tissues (review [8]). The brain PKC can be resolved 
into three types, type I, II and III, upon 
chromatography on a hydroxyapatite column 
[g-11]. The structure of each type has been iden- 
tified by comparison with the enzymes that were 
separately expressed in COS 7 cells transfected by 
the respective cDNA-containing plasmids [ IO,1 11. 
Type I has the structure encoded by y-sequence; 
type II is a mixture of the subspecies having PI- 
and @II-sequences, which are derived from a single 
RNA transcript by alternative splicing; and type 
III has the structure of a-sequence. These three 
types show subtle individual characteristics with 
slightly different kinetic and catalytic properties 
[ 12,131. Immunocytochemical and biochemical 
analysis has shown that the type I enzyme is ex- 
pressed only in central nervous tissues [ 14,151. This 
communication will describe that, among various 
subspecies tested, this brain-specific PKC 
titularly sensitive to phosphatidylethanol 
activation. 
is par- 
for its 
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2. MATERIALS AND METHODS 3. RESULTS 
2.1. Materials and chemicals 
Phosphatidylethanol and phosphatidylmethanol were 
prepared as described [16]. Phosphatidylserine and 1,2-diolein 
were obtained from Serdary Research Laboratories. Phos- 
phatidylethanolamine was obtained from Avanti Polar-Lipids. 
2.2. Purification and assay of PKC 
PKC was purified from the rat brain soluble fraction by 
DE-52, threonine-Sepharose and TSK phenyl-5PW column 
chromatographies, and was separated into three types, type I, 
II and III, by chromatography on a hydroxyapatite column 
connected to a Pharmacia FPLC system as described [lO,ll]. 
Each type of PKC was apparently homogeneous upon sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. PKC was 
assayed as described [17]. The reaction mixture (0.25 ml) con- 
tained 20 mM Tris-HCl at pH 7.5, 2OO,~g/ml calf thymus Hl 
histone, 10 pM [y-“P]ATP (So-150 cpm/pmol), 5 mM 
magnesium acetate, 0.01 mM EGTA (from enzyme fraction), 
each type of PKC (approximately 0.05 pg), and various 
amounts of CaCl2, phospholipids and 1 ,Zdiolein, as indicated 
in each experiment. Phospholipids and 1,2-diolein were mixed 
in a small amount of chloroform, dried under a nitrogen 
stream, and dispersed in 20 mM Tris-HCl at pH 7.5 by vigorous 
vortex mixing followed by sonication for 5 min at 4°C. The in- 
cubation was carried out for 3 min at 30°C and the reaction 
was terminated by the addition of 25% of trichloroacetic acid. 
Acid precipitable materials were collected on a nitrocellulose 
membrane and the radioactivity was quantitated by liquid scin- 
tillation counter. 
Table 1 
Distribution of PKC activity between the enzyme subspecies 
isolated from the soluble fraction of various tissue preparations 
Tissue Protein kinase activity (olo total) 
Type 1 Type II Type III 
Whole brain 
Cerebral cortex 
Hippocampus 
Cerebellum 
Spinal cord 
Sciatic nerve 
Liver 
Spleen 
Kidney 
26.1 49.1 
19.8 62.7 
24.9 40.5 
52.1 33.5 
3.2 49.7 
7.1 
31.3 
_ 67.5 
18.3 
24.8 
17.5 
34.6 
14.4 
47.1 
92.9 
68.7 
32.5 
81.7 
Tissue samples were homogenized in 20 mM Tris-HCI at pH 7.5 
containing 0.25 M sucrose, 10 mM EGTA, 2 mM EDTA, 
1 mM phenylmethylsulfonyl fluoride and 20 fig/ml leupeptin, 
and centrifuged at 100000 x g for 60 min. The supernatant was 
applied to a DEAR-cellulose column, followed by resolution of 
the partially purified enzyme subspecies on a hydroxyapatite 
column to a FPLC system (Pharmacia). PKC activity was 
assayed with 0.3 mM CaCl2, 0.8 pg/ml 1,2-diolein and 8 pg/ml 
phosphatidylserine as described in section 2 
As described elsewhere [9-l 11, the brain PKC 
was resolved into three major fractions, types I, II 
and III, upon hydroxyapatite column chromatog- 
raphy. Table 1 shows the relative distribution of 
the enzyme activity between the enzyme subspecies 
present in several regions of the brain and some 
other tissues. The identity of each type was con- 
firmed by immunoblot analysis with type-specific 
antibodies. The type II enzyme fraction is an une- 
qual mixture of PI- and @II-subspecies which can 
be distinguished thus far only by immunological 
procedures. The results show that a differential 
pattern of expression of the various subspecies is 
apparent in the tissues examined. In particular, 
type I enzyme encoded by y-sequence was found in 
the brain and spinal cord, but not in any of the 
other tissues or cell types so far tested. 
The enzyme subspecies isolated from various 
tissues required phospholipid for their catalytic ac- 
tivity, and phosphatidylserine was the most active 
at physiologically low concentrations of Ca2+. 
Table 2 shows the specificity of various phospho- 
lipids to support the enzymatic activity of the three 
types of PKC from rat whole brain. Phosphatidyl- 
inositol could activate the enzymes, and in addi- 
tion both phosphatidylethanol and phosphatidyl- 
methanol could substitute for phosphatidylserine, 
Table 2 
Activation of types I, II and III PKC by various phospholipids 
Phospholipid added Protein kinase activity (Vo) 
Type I Type II Type III 
Phosphatidylserine (8rg/ml) 100 100 100 
Phosphatidylinositol (8 ,ug/ml) 65 32 60 
Phosphatidylethanolamine 
(8rg/ml) 16 15 9 
Phosphatidylcholine (8 ag/ml) 3 2 2 
Sphingomyelin (5 pg/ml) 8 
Phosphatidylethanol (5 fig/ml) 67 3: 
2 
28 
Phosphatidylethanol (20 @g/ml) 63 24 23 
Phosphatidylmethanol (5 pg/ml) 48 45 44 
Phosphatidylmethanol 
(20 pg/ml) 46 31 31 
None 7 7 I 
PKC was assayed with 3 pM CaClz, 0.8 ,ug/ml 1,2-diolein and 
each phospholipid as indicated. Results are normalized to the 
activity obtained with phosphatidylserine. Other conditions are 
described in section 2 
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particularly for the activation of type 1 PKC. It 
was confirmed that at relatively higher concentra- 
tions of Ca2’ (0.3 mM) acidic phospholipids but 
not basic phospholipids could activate the enzyme. 
Fig. 1 provides further evidence that for the activa- 
tion of type 1 enzyme phosphatidylserine can be 
replaced by phosphatidylethanol and to a lesser ex- 
tent by phosphatidylmethanol (fig.lA). These 
phosphatidylalcohols were far less effective for 
type 11 and type 11 enzyme (fig.lB and 1C). Neither 
ethanol nor methanol affected the enzyme activa- 
tion at comparable concentrations, The result 
given in table 3 shows that the activation of type 1 
enzyme by phosphatidylalcohol is dependent of di- 
acylglycerol .
4. DISCUSSION 
Phospholipase D of plant origin was reported as 
early as 1967 by Dawson [18] and Yang et al. [16] 
to catalyze the phosphatidyltransferase reaction. 
Mammalian phospholipase D has been subse- 
quently shown to produce phosphatidylethanol 
[3,41, and the brain synaptosomal membrane 
possesses the highest activity [3]. It is worth noting 
that the phosphatidylethanol formation requires 
unsaturated fatty acids such as arachidonate and 
oleate, and that phosphatidylcholine is the most ef- 
PF~OSPBOLIPID (uq/ml) 
Fig. 1. The activation of three types of PKC by various concen- 
trations of phospholipids. PKC was assayed with 3 /tM CaC12, 
0.8 pg/ml l,Zdiolein, and various concentrations of each phos- 
pholipid as described in section 2. (A) Type I; (B) type II; (C) 
type III. (0) Phosphatidylethanol; (0) phosphatidylmethanol; 
(m) phosphatidylserine; (A) phosphatidylethanolamine. 
Table 3 
Effect of 1,2-diolein on type I PKC 
Phospholipid and diacylglycerol Protein kinase activity 
added 
cpm % 
Phosphatidylserine + 1 ,Zdiolein 13 880 100 
- 1 .2-diolein 2 480 8 
Phosphatidylethanol + 1 ,Zdiolein 11190 78 
- 1,2-diolein 3 760 19 
Phosphatidylmethanol + 1 ,Zdiolein 13400 96 
- 1,2-diolein 3 380 16 
none 14.50 
Type I PKC was assayed with 3 ,DM CaC12, 4 /cg/ml of each 
phospholipid, and with or without 0.8 pg/ml 1,2-diolein, as 
described in section 2 
fective phosphatidyl donor [3]. Although ethanol 
is one of the most common psychotropic agents, 
the mechanism of its behavioral and neurological 
effects remains to be clarified. At present, it is 
generally thought that ethanol exerts its biological 
effects on the lipids of the cell membranes [191. It 
was only recently that the presence of phos- 
phatidylethanol was in fact demonstrated in 
various tissues from ethanol-treated rats [5-71. The 
present studies suggest that this species of phos- 
pholipid can substitute for phosphatidylserine to 
activate PKC. This activation is most potent for 
the type 1 enzyme, encoded by y-sequence, which 
is apparently present only in the brain and spinal 
cord. This enzyme subspecies is abundant in the 
cerebellar cortex (Purkinje cells), hippocampus 
(pyramidal cells) and cerebral cortex. An earlier 
report [2] has shown that, although phosphatidyl- 
serine is indispensable, acidic phospholipids can 
potentiate the activation of PKC whereas phos- 
phatidylcholine and sphingomyelin are inhibitory. 
A possibility open to further study, therefore, is 
that ethanol may exert some of its biological ac- 
tions on neuronal tissues by modulating signal 
transduction through changes in protein phos- 
phorylation. 
NOTE ADDED IN PROOF 
We have recently learned that Dr Mordechai 
Liscovitch of the Department of Hormone 
Research, the Weizmann Institute, observed a 
stimulatory effect of phosphatidylethanol on an 
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stimulatory effect of phosphatidylethanol on an 
unfractionated mixture of rat brain PKC prepara- 
tions (personal communication). 
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